Indian Pharmaceutical Market

New regulatory and drug pricing policies are negatively impacting growth in the Indian pharmaceutical sector, but opportunities remain.

Highlights in this whitepaper include:

The effect of tighter regulations on the number of clinical trials conducted in India
The impact of inadequate patent protection for branded players and domestic generic manufacturers
The challenges faced with compulsory licensing of patented drugs
The result the expanding pricing controls will have on the multinational companies
Cheap generic medicines vs. branded manufacturers
Opportunities and challenges for multinational companies